ADJOURNMENT OF THE GENERAL MEETING INITALLY CONVENED ON JUNE 25, 2025NANTES, France, June 11, 6:30 PM – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), announces the cancellation of the convening of the mixed General Meeting initially scheduled for June 25, 2025 (the « General Meeting ») to clarify the situation. The Board of Directors will convene a new General Meeting within the allotted time frame. The Board of Directors of OSE Immunotherapeutics has acknowledged this judicial decision and has taken all necessary consequences. It will convene the General Meeting within the now allotted time frame. This period will allow for verifying the regularity and transparency of the General Meeting and ensuring shareholders are well informed.